Navigation Links
DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
Date:2/10/2009

LEIDEN, The Netherlands, and PARSIPPANY, N.J., Feb. 10 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Bioceros B.V. of Utrecht, The Netherlands to join their Vendor Network. Under the terms of the agreement, Bioceros will be a pre-approved cell line generation partner for licensees of the PER.C6(R) cell line located in the European Union.

Karen King, president of DSM Biologics notes, "The growing number of PER.C6(R) licensees requires that we expand the possibilities for our licensees to obtain services like cell line generation. We are confident that Bioceros' excellent experience and service level will provide our European licensees additional options to move their PER.C6(R) programs forward successfully."

Bram Bout, CEO of Bioceros added, "We are honored to achieve the distinction of being the first pre-approved Europe-based cell line generation partner using the PER.C6(R) cell line. The PER.C6(R) technology is recognized throughout our industry as providing important advantages compared to other platforms, including its well developed technology, which allow for short manufacturing timelines and exceptionally high productivity levels with off the shelf available culture media. The selection of Bioceros as a preferred Vendor by DSM and Crucell underscores the high quality of the services that we offer to our customers."

The PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. By employing the PER.C6(
'/>"/>

SOURCE DSM Biologics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
2. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
5. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
6. Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc.
7. ProCure Signs Agreement with .decimal, Inc. to Purchase Patient-Specific Devices for Its Proton Therapy Center in Oklahoma City
8. Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries
9. Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers
10. University of Helsinki and ASM International renew research agreement on atomic layer deposition
11. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Cereal grain scientists, ... will gather October 5–8, 2014, for the AACC ... Convention Center in Providence, Rhode Island. The comprehensive ... of food scientists, chemists, microbiologists, nutritionists, and those ... production management. To date, 1,000 attendees have registered ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
Breaking Biology Technology:Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the ... treated in a Phase 1b clinical trial of ... a proprietary small molecule,inhibitor of thioredoxin, a protein ... growth, survival and drug resistance of,many cancers., ...
... to Healthcare Organizations through CSC,s ... ... CSC (NYSE: CSC ) today,announced that its enterprise ... FirstPortfolio offering.,FirstPoint streamlines a health organization,s document management,processes and incorporates ...
... (OTC BB BSTC.OB-News) today announced that it sold ... stock priced at $15,per share for aggregate proceeds ... certain private investors on June 9, 2008. The ... at a premium over the,market price., BioSpecifics ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3CSC Adds Content Management to Hosted Healthcare Offering 2
(Date:9/21/2014)... years, new strains of bacteria have emerged that resist ... including drug-resistant forms of tuberculosis and staphylococcus, infect more ... 23,000. Despite the urgent need for new treatments, scientists ... the past decade. , MIT engineers have now turned ... gene-editing system that can disable any target gene, they ...
(Date:9/21/2014)... a protein therapy that disrupts the process that causes ... travel through the blood stream and start aggressive new ... as metastasis, can cause cancer to spread with deadly ... to cancer fall prey to metastatic forms of the ... who describes a new therapeutic approach in Nature ...
(Date:9/19/2014)... professor will study the unique bioelectric signaling system of ... people,s health. The OU researcher is working to ... produce the signals used to map the world around ... rate of 500-600 discharges a second throughout their lives. ... are extreme, but necessary for survival. , "There is ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... imaging technique to track the effects of next-generation nanomedicines ... Strathclyde academic. Professor Dr. M. N. V. Ravi ... of Pharmacy and Biomedical Sciences, believe an advanced form ... boost developments in the field of nanomedicines, the encapsulation ...
... the collaboration between Janssen, J&J Innovation, VIB, KU Leuven ... in translating basic molecular insights to diagnostics and therapeutics ... are committing up to 5 million Euros for this ... research projects from VIB, KU Leuven and UZ Leuven. ...
... obesity, endocrine-disrupting chemicals, adolescent health and clinical trials will be ... The 95th Annual Meeting & Expo of The Endocrine Society. ... 15 Adolescent Health (10 a.m. PDT): New insights ... conditions including eating disorders and gender identity disorder. ...
Cached Biology News:Nanomedicines' impact on patients under the microscope 2Nanomedicines' impact on patients under the microscope 3Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven join forces to combat neurological diseases 2
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... 2800mL PYREX Fernbach-style culture flasks have triple ... flask bottom to achieve maximal oxygen transfer ... large marking spot., A wide range of ... including:, Polypropylene colored caps for ease ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Biology Products: